Clinical Trial Update: A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating camrelizumab with paclitaxel albumin-bound and gemcitabine as first-line therapy for metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Gemcitabine (Gemcitabine)
• Paclitaxel (albumin-bound) (paclitaxel albumin-bound)

Snippet

Sponsor: RenJi Hospital | Conditions: Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic | Phase 3 | Status: UNKNOWN